What's Happening?
AstraZeneca's Lokelma, a therapy for high potassium levels in the blood, is set to see wider usage in the NHS following a NICE update. The new guidance lowers the potassium threshold for treatment eligibility from 6.0 mmol/L to 5.5 mmol/L and removes
the requirement for specialist initiation. This change is based on real-world evidence showing the drug's effectiveness in managing hyperkalaemia, a condition often associated with chronic kidney disease and heart failure. The update is part of a broader adjustment in NICE's cost-effectiveness threshold, which now ranges from £25,000 to £35,000 per quality adjusted life year.
Why It's Important?
The NICE update significantly increases the number of patients eligible for Lokelma, potentially improving outcomes for those with chronic kidney disease and heart failure. By allowing earlier intervention, the new guidance helps maintain patients on effective treatments, reducing the risk of serious complications. This change reflects a shift towards more proactive management of hyperkalaemia, aligning with modern healthcare practices. The update also highlights the importance of real-world evidence in shaping healthcare policies and ensuring that effective, evidence-based medicines reach more patients.
